Key Events This Week
16 Mar: New 52-week low (Rs.134.8)
18 Mar: Valuation shifts signal attractive entry amid sector challenges
20 Mar: Week closes at Rs.138.25 (-1.21%)
16 March: Stock Hits 52-Week Low Amid Persistent Downtrend
On 16 March 2026, Piramal Pharma Ltd’s stock reached a fresh 52-week low of Rs.134.8 intraday, closing at Rs.138.65, down 0.93% from the previous close. This decline was part of a broader four-day losing streak that saw the stock fall by 12.44%. The day’s drop was significant against the backdrop of a resilient Sensex, which gained 0.47% to close at 33,673.11. The stock’s underperformance was driven by ongoing negative financial results, including a steep decline in profitability and earnings per share.
Financially, the company reported a Profit Before Tax (excluding other income) of Rs. -95.99 crores, a dramatic 2,577.2% decrease compared to the previous four-quarter average. Profit After Tax also plunged by 755.0% to Rs. -95.08 crores, with EPS at a negative Rs. -1.03. These figures underscore the company’s severe earnings pressure, contributing to the bearish technical indicators and a downgrade to a Strong Sell Mojo Grade.
Technically, the stock traded below all key moving averages, signalling a bearish trend. The Moving Average Convergence Divergence (MACD) and Bollinger Bands indicators confirmed this negative momentum on weekly and monthly timeframes. Institutional holdings remain substantial at 45.35%, but this has not prevented the stock’s sharp decline.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
18 March: Valuation Shifts Signal Potential Value Despite Sector Challenges
Midweek, on 18 March, Piramal Pharma’s valuation metrics attracted attention as the stock traded at Rs.143.15, up 2.91% for the day, outperforming the Sensex’s 1.15% gain. The company’s price-to-earnings (P/E) ratio remained deeply negative at -128.57, reflecting ongoing earnings losses. However, the price-to-book value (P/BV) ratio of 2.28 suggested the stock was trading at a modest premium to net asset value, relatively attractive compared to sector peers such as Wockhardt and Sai Life Sciences, which command much higher multiples.
Enterprise value to EBITDA (EV/EBITDA) stood at 22.04, elevated but still below some large-cap pharmaceutical companies. Profitability metrics remained weak, with a return on capital employed (ROCE) of 2.66% and a negative return on equity (ROE) of -0.55%. These figures highlight the company’s ongoing challenges in generating returns despite a five-year operating profit growth CAGR of 111.53% and net sales growth of 7.96%.
Despite the valuation appeal, the stock’s year-to-date decline of 19.59% and one-year fall of 32.69% underscore persistent investor caution. The Mojo Grade remains at Strong Sell, reflecting concerns over earnings quality and near-term outlook. Nonetheless, the valuation shift may offer an entry point for investors with a higher risk tolerance and a long-term perspective.
Piramal Pharma Ltd or something better? Our SwitchER feature analyzes this small-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
19-20 March: Volatility Amid Market Correction
On 19 March, the stock declined sharply by 5.17% to Rs.135.75, mirroring a significant Sensex drop of 3.13% amid broader market weakness. This day’s volume surged to 218,889 shares, indicating heightened selling pressure. The decline reflected continued investor concerns over the company’s financial health and sector headwinds.
However, on 20 March, Piramal Pharma rebounded by 1.84% to close at Rs.138.25, supported by a 0.51% gain in the Sensex. The recovery was accompanied by a volume of 169,590 shares, suggesting some buying interest at lower levels. Despite this bounce, the stock ended the week below its opening price, reflecting ongoing volatility and uncertainty.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-16 | Rs.138.65 | -0.93% | 33,673.11 | +0.47% |
| 2026-03-17 | Rs.139.10 | +0.32% | 33,940.18 | +0.79% |
| 2026-03-18 | Rs.143.15 | +2.91% | 34,329.13 | +1.15% |
| 2026-03-19 | Rs.135.75 | -5.17% | 33,255.16 | -3.13% |
| 2026-03-20 | Rs.138.25 | +1.84% | 33,423.61 | +0.51% |
Key Takeaways
Negative Signals: The stock’s fresh 52-week low and sustained losses over the week highlight ongoing financial and operational challenges. Weak profitability metrics, including a negative EPS and low ROCE, continue to weigh on investor sentiment. The downgrade to a Strong Sell Mojo Grade reflects these concerns.
Positive Signals: Despite near-term earnings pressure, the valuation shift to an attractive rating based on P/BV and EV/EBITDA multiples suggests potential value for long-term investors. The stock’s five-year operating profit growth CAGR of 111.53% and net sales growth of 7.96% indicate underlying business resilience. The rebound on 18 and 20 March shows some buying interest amid volatility.
Conclusion
Piramal Pharma Ltd’s week was characterised by volatility and mixed signals. The stock’s decline of 1.21% contrasted with a milder Sensex fall, underscoring company-specific challenges amid a cautious market environment. The fresh 52-week low and weak profitability metrics remain cautionary, while valuation shifts offer a nuanced perspective on potential entry points. Investors should monitor upcoming financial disclosures and sector developments closely to gauge the stock’s trajectory in the near term.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
